DH9 study results according to treatment arm and International Prognostic Score (IPS).
| . | Standard BEACOPP N = 469 . | Escalated BEACOPP N = 466 . | COPP/ABVD N = 260 . | |||
|---|---|---|---|---|---|---|
| . | 5 y . | 10 y . | 5 y . | 10 y . | 5 y . | 10 y . |
| *P = .015 | ||||||
| †P = .0001 | ||||||
| ‡P = .020 | ||||||
| §P = .0027 | ||||||
| Abbreviations: BEACOPP, cyclophosphamide, adriamycin, etoposide, vincristine, bleomycin, procarbazine, prednisone; COPP/ABVD, cyclophosphamide, vincristine, prednisone, procarbazine/adriamycin, bleomycin, vinblastine, dacarbazine; FFS, failure-free survival; OS, overall survival. | ||||||
| FFS, % | ||||||
| IPS 0,1 | 81 | 79 | 92 | 91* | 79 | 78* |
| IPS 2,3 | 72 | 71 | 87 | 83† | 67 | 59† |
| IPS 4–7 | 74 | 56 | 82 | 71‡ | 59 | 54‡ |
| OS, % | ||||||
| IPS 0,1 | 93 | 85 | 95 | 94 | 92 | 88 |
| IPS 2,3 | 86 | 84 | 90 | 87§ | 84 | 73§ |
| IPS 4–7 | 81 | 63 | 82 | 70 | 67 | 61 |
| . | Standard BEACOPP N = 469 . | Escalated BEACOPP N = 466 . | COPP/ABVD N = 260 . | |||
|---|---|---|---|---|---|---|
| . | 5 y . | 10 y . | 5 y . | 10 y . | 5 y . | 10 y . |
| *P = .015 | ||||||
| †P = .0001 | ||||||
| ‡P = .020 | ||||||
| §P = .0027 | ||||||
| Abbreviations: BEACOPP, cyclophosphamide, adriamycin, etoposide, vincristine, bleomycin, procarbazine, prednisone; COPP/ABVD, cyclophosphamide, vincristine, prednisone, procarbazine/adriamycin, bleomycin, vinblastine, dacarbazine; FFS, failure-free survival; OS, overall survival. | ||||||
| FFS, % | ||||||
| IPS 0,1 | 81 | 79 | 92 | 91* | 79 | 78* |
| IPS 2,3 | 72 | 71 | 87 | 83† | 67 | 59† |
| IPS 4–7 | 74 | 56 | 82 | 71‡ | 59 | 54‡ |
| OS, % | ||||||
| IPS 0,1 | 93 | 85 | 95 | 94 | 92 | 88 |
| IPS 2,3 | 86 | 84 | 90 | 87§ | 84 | 73§ |
| IPS 4–7 | 81 | 63 | 82 | 70 | 67 | 61 |